TOP TEN perturbations for 1552377_s_at (Homo sapiens)

Organism: Homo sapiens
Gene: 1552377_s_at
Selected probe(set): 1552377_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 1552377_s_at (1552377_s_at) across 6673 perturbations tested by GENEVESTIGATOR:

alopecia areata study 1 (AU; lesional; validation) / alopecia areata study 1 (AU; lesional; discovery)

Relative Expression (log2-ratio):-1.372015
Number of Samples:9 / 14
Experimental alopecia areata study 1 (AU; lesional; validation)
Lesional scalp skin punch biopsies obtained from patients who suffered from alopecia areata universalis (AU) assigned to validation dataset.
Control alopecia areata study 1 (AU; lesional; discovery)
Lesional scalp skin punch biopsies obtained from patients who suffered from alopecia areata universalis (AU) assigned to discovery dataset.

HIV-associated neurocognitive disorder study 4 (ischemia) / normal genu sample

Relative Expression (log2-ratio):1.3244343
Number of Samples:2 / 8
Experimental HIV-associated neurocognitive disorder study 4 (ischemia)
Postmortem brain samples of the centrum semiovale (deep white matter) at the coronal level of the genu of the corpus callosum from patients with ischemia. The patients did not receive any antiretroviral therapy (ART).
Control normal genu sample
Postmortem brain samples of the centrum semiovale (deep white matter) at the coronal level of the genu of the corpus callosum from healthy subjects.

HIF-1a/HIF-2a depletion study 1 (hypoxia; HK2) / HIF-1a/HIF-2a depletion study 1 (normoxia; AB81)

Relative Expression (log2-ratio):-1.2654858
Number of Samples:3 / 3
Experimental HIF-1a/HIF-2a depletion study 1 (hypoxia; HK2)
Proximal tubule epithelial cell line HK-2 with shRNA-mediated stable knock-down of HIF-1a and HIF-2a (Hypoxia-inducible factor 1-alpha and Hypoxia-inducible factor 2-alpha) 24 hours after treatment with hypoxia (20% O2). HK-2 cells were cultured in DMEM/F-12 supplemented with 10% fetal calf serum (FCS), 1% ITS, hydrocortisone, and antibiotics. The cells were incubated at 37 °C.
Control HIF-1a/HIF-2a depletion study 1 (normoxia; AB81)
Human podocyte cells AB81 with shRNA-mediated stable knock-down of HIF-1a and HIF-2a (Hypoxia-inducible factor 1-alpha and Hypoxia-inducible factor 2-alpha) 24 hours after treatment with normoxia (20% O2). Conditionally immortalized human podocytes AB81 were cultured under permissive conditions (33 °C) in RPMI-1640 supplemented with 10% FBS, antibiotics, and 1% ITS. Differentiation was induced by thermoshift to 37 °C in 6-well plates.

glioma study 16 (LN-18) / normal astrocyte sample

Relative Expression (log2-ratio):-1.1911917
Number of Samples:2 / 3
Experimental glioma study 16 (LN-18)
Human glioma cell line LN018 was cultured in DMEM supplemented with 10% FCS (fetal calf serum) and antibiotics at 37C and 5% CO2.
Control normal astrocyte sample
Normal brain astrocytes. Clonetics normal human astrocytes (NHA) from Cambrex (primary-derived cultures) and cultured according to the manufacturer's recommendations.

memory B cell study 1 (CD27high) / memory B cell study 1 (undivided)

Relative Expression (log2-ratio):1.0779591
Number of Samples:6 / 6
Experimental memory B cell study 1 (CD27high)
CD27 enriched proliferating human memory B cells expressing high level of CD27 (marker of antibody secretion) activated with CpG oligodeoxynucleotide (10 ng/ml), recombinant human cytokines IL-2 (20 IU/ml), IL-10 (50 ng/ml), IL-15 (10 ng/ml), recombinant human BAFF (75 ng/ml) in PC-L medium (IMDM medium, lacromin (50mg/ml), insulin (5mg/ml), penicillin/streptomycin, gentamicin (15mg/ml), normocin (0.1% v/v), 10% FCS) for 80 hours.
Control memory B cell study 1 (undivided)
CD27 enriched undivided human memory B cells (expressing low level of CD27) activated with CpG oligodeoxynucleotide (10 ng/ml), recombinant human cytokines IL-2 (20 IU/ml), IL-10 (50 ng/ml), IL-15 (10 ng/ml), recombinant human BAFF (75 ng/ml) in PC-L medium (IMDM medium, lacromin (50mg/ml), insulin (5mg/ml), penicillin/streptomycin, gentamicin (15mg/ml), normocin (0.1% v/v), 10% FCS) for 80 hours.

atopic dermatitis study 12 (non-lesional; adults) / atopic dermatitis study 12 (non-lesional; children)

Relative Expression (log2-ratio):-1.0745974
Number of Samples:20 / 19
Experimental atopic dermatitis study 12 (non-lesional; adults)
Unaffected skin biopsy samples from adult patients (age range 18-73 years) with long-standing atopic dermatitis.
Control atopic dermatitis study 12 (non-lesional; children)
Unaffected buttock skin biopsy samples from pediatric patients (age range 3 months-5 years) with early-onset atopic dermatitis. All patients had moderate-to-severe disease (SCORAD score: mean, 57.8; range, 33-84) with recent-onset (within the previous 6 months). Systemic immunosuppressants within the past 4 weeks, topical steroids or immunomodulators within 1 week, or moisturizers within 12 hours before evaluation were restricted. Patients with active skin infections were excluded.

bisacodyl study 4 (3975ng/ml) / vehicle (DME) treated bronchial epithelial cell sample

Relative Expression (log2-ratio):1.0267582
Number of Samples:3 / 17
Experimental bisacodyl study 4 (3975ng/ml)
Bronchial epithelial cells (NHBE) treated with bisacodyl (3975ng/ml; vendor: Prestwick Chemical / catalog number: 419 / catalog name: Bisacodyl [603-50-9]) for 6 hours. For treatment primary cells were seeded at a density of 50'000 cells/well in pre-coated rat tail collagen type I 96-well plates for 24 hours followed by 4 hours starvation. NHBE cells were isolated from different Caucasian, healthy and non-smoker donors from the airway located above the bifurcation of the lungs (tracheal/bronchial). ATC code:, ,
Control vehicle (DME) treated bronchial epithelial cell sample
Bronchial epithelial cells (NHBE) treated with vehicle (DME) for 6 hours. For treatment primary cells were seeded at a density of 50'000 cells/well in pre-coated rat tail collagen type I 96-well plates for 24 hours followed by 4 hours starvation. NHBE cells were isolated from different Caucasian, healthy and non-smoker donors from the airway located above the bifurcation of the lungs (tracheal/bronchial).

Langerhans cell histiocytosis study 4 / normal tonsillar T-lymphocyte sample

Relative Expression (log2-ratio):-0.94036865
Number of Samples:7 / 4
Experimental Langerhans cell histiocytosis study 4
CD3+ T-lymphocyte samples isolated from peripheral blood of patients with Langerhans cell histiocytosis, prior to chemotherapy treatment. Patient with different clinical status were included in this study (unifocal, single system and multifocal, single system disease).
Control normal tonsillar T-lymphocyte sample
Normal tonsillar CD3+ T-lymphocytes were isolated from children who undergone elective tonsillectomy. The T-cells were isolated from presumably healthy tissue.

engineered skin substitute study 2 (intermediate) / engineered skin substitute study 1 (intermediate)

Relative Expression (log2-ratio):0.9190407
Number of Samples:6 / 3
Experimental engineered skin substitute study 2 (intermediate)
Human skin substitutes tissue samples collected after 14 and 28 days after transplantation to athymic mice.
Control engineered skin substitute study 1 (intermediate)
Human skin substitutes tissue samples collected after 7 days in culture.

catechol study 2 (3300ug/ml) / vehicle (EtOH) treated bronchial epithelial cell sample

Relative Expression (log2-ratio):0.9161949
Number of Samples:3 / 3
Experimental catechol study 2 (3300ug/ml)
Bronchial epithelial cells (NHBE) treated with 3300 ug/ml catechol (within range of concentrations reported to induce toxicity in lung epithelial cells and other cell types) for 8 hours. NHBE cells were derived from a 60 year old male non-smoker. ATC code:---
Control vehicle (EtOH) treated bronchial epithelial cell sample
Bronchial epithelial cells (NHBE) treated with vehicle (ethanol) at a final concentration of 2% v/v (concentration that ensures >80% cell viability after 24 hours of exposure) for 8 hours. NHBE cells were derived from a 60 year old male non-smoker.